Publication: Recommended dose of alfacacidol for osteoporosis
| dc.contributor.author | Narong Bunyaratavej | en_US |
| dc.contributor.other | Mahidol University | en_US |
| dc.date.accessioned | 2018-05-03T08:24:33Z | |
| dc.date.available | 2018-05-03T08:24:33Z | |
| dc.date.issued | 2011-10-01 | en_US |
| dc.description.abstract | The present study aims to investigate a proper dose of alfacalcidol by using the parathyroid level as a marker due to the end product of alfacalcidol is calcitriol which has a property of suppression secretion of parathyroid glands. The research enrolled 259 volunteers which were divided into 2 groups. Each group took the elemental calcium 800 milligram plus alfacalcidol at the different doses. Group (A) received alfacalcidol 1.0 microgram/day and Group (B) had alfacalcidol 1.5 micrograms/day for 3 months. Group (A) could not suppress the secretion of PTH compared with Group (B) of which the PTH level was decreased significantly (p = 0.047). Alfacalcidol in both groups can not decrease the bone resorption monitored by using the bone resorption marker, BetacrossLaps or bCTx. | en_US |
| dc.identifier.citation | Journal of the Medical Association of Thailand. Vol.94, No.10 SUPPL. (2011) | en_US |
| dc.identifier.issn | 01252208 | en_US |
| dc.identifier.other | 2-s2.0-84858033850 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/12271 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858033850&origin=inward | en_US |
| dc.subject | Medicine | en_US |
| dc.title | Recommended dose of alfacacidol for osteoporosis | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84858033850&origin=inward | en_US |